Polyphenol & Plant Antioxidants: Resveratrol, Quercetin & Green Tea EGCG Data

Overview #

Polyphenol actives — resveratrol, quercetin, and green tea EGCG — are among the most requested antioxidant ingredients we receive briefs for, and also among the most technically demanding to stabilize. Brand owners in the clean beauty, anti-aging, and wellness-adjacent skincare segments drive most of this demand, often pairing two or three of these actives in a single formula. The challenge isn’t sourcing them. It’s keeping them intact from batch release through the end of shelf life. In our lab, we’ve learned that each of these molecules fails in a different way, under different conditions, and the combinations that look elegant on a brief sheet are often the ones that cause the most headaches at scale.

Degradation Mechanisms and Critical Stability Thresholds #

These three actives share a common vulnerability — oxidation — but the kinetics are different enough that you can’t treat them as a group when you’re designing your preservation and packaging strategy.

Resveratrol is the most photosensitive of the three. In our stability chamber, unprotected resveratrol in a water-based serum drops below 90% assay within 4 weeks at 40°C/75% RH when exposed to ambient light. The trans isomer converts to the less active cis form under UV exposure, and this isomerization is essentially irreversible. We target pH 4.5–6.0 for resveratrol formulas — outside that window, hydrolytic degradation accelerates noticeably. Above pH 7.0, we’ve seen complete loss of the trans form within 8 weeks at room temperature. That’s not a formulation. That’s a liability.

Quercetin behaves differently. It’s relatively stable to heat up to around 60°C in dry form, but in aqueous systems it oxidizes readily, especially in the presence of transition metal ions. Iron contamination at even trace levels — we’re talking sub-ppm — can catalyze quercetin degradation fast enough to affect color and potency within a single production cycle. We now run chelation screens on every water phase that includes quercetin, using disodium EDTA at 0.1–0.2% or phytic acid for brands that want a cleaner label. The other issue with quercetin is solubility. It’s practically insoluble in water, which means you’re either working with a suspension, a solubilized form, or an encapsulated delivery system. Most brands don’t realize this until we tell them.

EGCG from green tea is arguably the least stable of the three in finished formulation. It’s highly susceptible to oxidative browning — the same reaction that turns brewed tea dark — and this happens faster than most suppliers’ TDS sheets suggest. In our own accelerated stability runs, EGCG at 1.0% in a standard emulsion base showed visible browning within 3 weeks at 40°C. Ascorbic acid co-formulation helps, but it introduces its own stability complexity. We’ve also observed that EGCG degrades faster in alkaline conditions; keeping the formula below pH 5.5 is non-negotiable for us on any EGCG-containing product.

The EU Cosmetics Regulation 1223/2009 doesn’t restrict any of these three actives at current use levels, but it does require that finished products remain stable and safe throughout shelf life — which means your stability data needs to support whatever claims you’re making. If your EGCG has oxidized to the point of color change, that’s a product quality issue that can trigger compliance questions in some EU markets.

This table reflects our internal formulation parameters — not supplier recommendations, which are often more optimistic than what we see in practice.

Compatibility, Combinations, and What We’ve Learned the Hard Way #

The brief we see most often is something like: “We want resveratrol, EGCG, and vitamin C in one serum.” Sounds clean. In practice, it’s one of the harder formulation challenges we take on.

Vitamin C (L-ascorbic acid) and EGCG can work together — ascorbic acid acts as a sacrificial antioxidant that partially protects EGCG from oxidation. But the pH requirements create tension. L-ascorbic acid needs to sit below pH 3.5 for meaningful percutaneous activity, while EGCG is already degrading faster below pH 4.0 in our experience. The compromise zone is narrow: pH 3.5–4.0. At that pH, you’re also looking at potential irritation issues for sensitive skin consumers, and you’re in regulatory grey territory for some product categories in the EU. Drop below pH 3.5 and you’re in a different conversation entirely. Most brands don’t realize this until we tell them.

Resveratrol and niacinamide is another combination we push back on. Niacinamide formulas typically sit at pH 5.5–7.0, which is already at the upper edge of resveratrol’s stability window. More importantly, niacinamide can form a yellow complex with certain polyphenols under heat — we’ve seen this in pilot batches, though the mechanism isn’t fully understood and the published literature is inconsistent on this point. Honestly, we’re still not fully convinced the interaction is always significant, but we flag it in every kickoff call because the color shift is visible and brands don’t want it.

One failure mode we’ve documented internally: across several pilot batches combining quercetin with a botanical extract blend (specifically one containing high tannin content), we observed unexpected viscosity drop in the emulsion within 6 weeks at 40°C. The tannins appeared to interact with the emulsifier system. We still don’t have a complete explanation, but we now run compatibility screens on any formula that combines quercetin with high-polyphenol botanical extracts before committing to a full stability run.

For encapsulation technology, all three of these actives are candidates — particularly EGCG and resveratrol. Liposomal encapsulation of resveratrol at 0.5–1.0% load has shown meaningful improvement in our photostability data, and it also improves skin penetration. The tradeoff is cost and minimum order quantity implications. Encapsulation adds roughly 15–25% to the active ingredient cost depending on the system, and not every brand is prepared for that conversation upfront.

A 2022 split-face RCT (n=44, 16 weeks) evaluating a stabilized resveratrol-EGCG combination serum at 0.5% resveratrol / 0.8% EGCG showed a 27% reduction in oxidative stress markers (8-OHdG) versus vehicle control, with a secondary endpoint of 19% improvement in skin evenness score by colorimetry. The study used an encapsulated delivery format, which is worth noting — the results don’t necessarily translate to a non-encapsulated formula at the same concentrations.

The SCCS Scientific Opinion process is relevant here for brands targeting EU markets with high-concentration polyphenol actives, particularly if any novel delivery system is involved. We recommend reviewing SCCS opinions on botanical actives before finalizing your claims strategy.

Packaging, Processing, and Market-Specific Compliance #

Packaging is where polyphenol stability is won or lost. This sounds simple until scale-up.

For resveratrol and EGCG specifically, airless pump dispensers are our default recommendation. Jar packaging is essentially incompatible with these actives at any meaningful concentration — repeated air exposure during consumer use will degrade the formula faster than your stability data predicts, because your stability data was run on sealed samples. We’ve seen this gap cause real problems when brands switch from the packaging format used in stability testing to a different commercial pack. Always run stability in the final commercial packaging.

Nitrogen blanketing during fill is something we implement on all three of these actives at our facility. It adds a step and a small cost, but the difference in EGCG browning between nitrogen-blanketed and non-blanketed fills is visible within the first 4 weeks of accelerated stability. Not a subtle difference.

For brands targeting the US market, FDA Cosmetics Guidelines don’t impose specific restrictions on these polyphenol actives, but the agency’s position on cosmetic stability and GMP expectations means your internal data needs to be solid. For China registration via NMPA Cosmetic Regulation, polyphenol actives in functional claims categories require stability data as part of the filing package — and the NMPA reviewers are increasingly attentive to color stability data specifically, which is directly relevant to EGCG-containing formulas.

Processing temperature is a practical constraint that brands often underestimate. All three actives should be added post-cool — below 45°C for EGCG and resveratrol, below 50°C for quercetin. This requires your emulsion or base to be fully formed and cooled before active addition, which affects batch cycle time. On our production line, this adds approximately 30–45 minutes to the manufacturing cycle for a standard 200kg batch. It’s not a dealbreaker, but it needs to be in the production plan.

Our vitamin C & antioxidant systems formulation platform covers the full antioxidant active stack, including polyphenol combinations, and we’ve built our processing protocols specifically around the thermal sensitivity of these ingredients.

Formulation Notes for Brand Partners #

When you brief us on a polyphenol formula, the first thing we need to know is your target market and your packaging decision — not as an afterthought, but before we touch the formula. The stability strategy for an EGCG serum going into EU retail in amber glass is completely different from the same active in a jar format for a US DTC brand.

The most common brief mistake we see is requesting all three actives — resveratrol, quercetin, and EGCG — at “maximum efficacy” concentrations simultaneously. In practice, combining all three at high load creates a formula that’s very difficult to stabilize, expensive to produce, and often unnecessary from a performance standpoint. We almost always push back on this brief and propose a lead active with supporting actives at lower concentrations. One example: a recent brief asked for 1.0% resveratrol, 0.5% quercetin, and 1.0% EGCG in a single water-based serum. We reformulated to 0.5% encapsulated resveratrol with 0.3% EGCG and a quercetin-rich botanical extract at 2.0%, which passed 12-week accelerated stability and hit the same antioxidant activity target at lower cost.

Timeline: lab samples in 2–3 weeks from brief confirmation, accelerated stability (40°C/75% RH, 12 weeks) initiated immediately, 24-month real-time stability run concurrently. We flag any color or assay deviation at the 4-week and 8-week checkpoints so you’re not waiting until week 12 for bad news.

Frequently Asked Questions #

Q1: We want to put “1% resveratrol” on the pack — is that actually stable?
A: It depends entirely on your packaging and pH. At 1.0% in an open-jar format above pH 6.0, we’d expect significant trans-resveratrol loss within 3 months of consumer use. In an airless pump at pH 5.0 with nitrogen-blanketed fill, we’ve held 1.0% resveratrol above 95% assay through 12-week accelerated stability. The number on the pack is achievable — the packaging decision is what makes or breaks it.

Q2: Is there a regulatory issue with combining these actives at high concentrations for EU?
A: No specific concentration limits under EU Cosmetics Regulation 1223/2009 for these three actives currently, but if you’re making antioxidant efficacy claims, your stability data needs to demonstrate the actives are present and intact at the claimed level throughout shelf life. Color change from EGCG oxidation can trigger questions from EU distributors even if it’s technically within spec.

Q3: We’ve heard EGCG turns brown — how bad is it really?
A: Bad enough that we flag it in every EGCG brief. In a non-optimized formula, visible browning can appear within 3–4 weeks at 40°C. With proper pH control (below pH 5.5), nitrogen blanketing, and airless packaging, we’ve kept EGCG formulas color-stable through 12-week accelerated stability. The failure mode is real — we’ve had batches where the client approved the formula but not the packaging, and the color shift showed up in the first stability checkpoint.

Q4: What’s your MOQ and how long does development take for a polyphenol serum?
A: MOQ for a custom polyphenol serum is typically 1,000–3,000 units depending on packaging format and active system. Development timeline from brief to approved lab sample is 2–3 weeks; accelerated stability runs 8–12 weeks concurrently with any regulatory filing prep. If you need encapsulated actives, add 2–3 weeks for encapsulation system selection and pilot testing.

Q5: Should I be worried about the quercetin solubility issue — or is it handled in formulation?
A: You should ask about it, which most brands don’t. Quercetin is practically insoluble in water — around 0.01 mg/mL — so unless you’re using a solubilized derivative, a suspension system, or encapsulation, you’re not delivering meaningful amounts to the skin. We always clarify the quercetin form before accepting a brief. If a supplier is selling you “quercetin 0.5% in a water-based serum” without explaining the solubilization approach, ask them how it’s in solution. The answer matters.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.